Validation of Calculated Globulin (CG) as a Screening Test for Antibody Deficiency in an Italian University Hospital / Antonio Pecoraro, Stephen Jolles, Ludovica Crescenzi, Gilda Varricchi, Giancarlo Marone, Marcella Savoia, Arturo Genovese, Giuseppe Spadaro
Background: Morbidity and mortality of primary and secondary antibody deficiencies (AD) are frequently associated with diagnostic delays. These could be avoided by a combination of factors including a widespread and effective development in screening tests. Methods: Calculated globulin (CG), derived from the difference between serum total protein and albumin levels, reflects immunoglobulin serum levels and has shown to have a predictive value in the early diagnosis of antibody deficiencies. This study investigated the possibility to use low levels of CG to detect antibody deficiency in an Italian University Hospital. Results: First, we conducted an analysis of anonymized adult samples collected at our biochemistry laboratory with a range of calculated globulin levels from 15 to 22 g/l. A CG cut-off of 19 g/l detected subjects with IgG lower than 600 mg/dl with a sensitivity of 70% and a specificity of 75%. To further verify the clinical usefulness of CG, we retrospectively evaluated the relationship between CG values and serum IgG levels in 38 patients diagnosed with CVID at our Institution. Using a CG cut-off of 19 g/l, we detected antibody deficiency in 97.3% (37/38) of the subjects present in our cohort. Conclusion: Finally, we chose a CG value of 19 g/l as the cut-off for a prospective AD screening program. The results of this study show that a screening CG test can be used as a tool to reduce diagnostic delays, improve long-term prognosis and reduce the healthcare costs of antibody deficiency.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2018 |
---|---|
Erschienen: |
2018 |
Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
---|---|
Enthalten in: |
Current pharmaceutical biotechnology - 19(2018), 9, Seite 728- |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Pecoraro, Antonio [VerfasserIn] |
---|
Links: |
FID Access [lizenzpflichtig] |
---|
Umfang: |
1 Online-Ressource (6 p) |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
KFL009058605 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | KFL009058605 | ||
003 | DE-627 | ||
005 | 20231128170941.0 | ||
007 | cr uuu---uuuuu | ||
008 | 220323s2018 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)KFL009058605 | ||
035 | |a (KFL)prod_DARH_.683DF17F84475AD4A85196CEA1A65C41D92F27D9 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
084 | |a PHARM |q DE-84 |2 fid | ||
100 | 1 | |a Pecoraro, Antonio |e verfasserin |4 aut | |
245 | 1 | 0 | |a Validation of Calculated Globulin (CG) as a Screening Test for Antibody Deficiency in an Italian University Hospital |c Antonio Pecoraro, Stephen Jolles, Ludovica Crescenzi, Gilda Varricchi, Giancarlo Marone, Marcella Savoia, Arturo Genovese, Giuseppe Spadaro |
264 | 1 | |c 2018 | |
300 | |a 1 Online-Ressource (6 p) | ||
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Background: Morbidity and mortality of primary and secondary antibody deficiencies (AD) are frequently associated with diagnostic delays. These could be avoided by a combination of factors including a widespread and effective development in screening tests. Methods: Calculated globulin (CG), derived from the difference between serum total protein and albumin levels, reflects immunoglobulin serum levels and has shown to have a predictive value in the early diagnosis of antibody deficiencies. This study investigated the possibility to use low levels of CG to detect antibody deficiency in an Italian University Hospital. Results: First, we conducted an analysis of anonymized adult samples collected at our biochemistry laboratory with a range of calculated globulin levels from 15 to 22 g/l. A CG cut-off of 19 g/l detected subjects with IgG lower than 600 mg/dl with a sensitivity of 70% and a specificity of 75%. To further verify the clinical usefulness of CG, we retrospectively evaluated the relationship between CG values and serum IgG levels in 38 patients diagnosed with CVID at our Institution. Using a CG cut-off of 19 g/l, we detected antibody deficiency in 97.3% (37/38) of the subjects present in our cohort. Conclusion: Finally, we chose a CG value of 19 g/l as the cut-off for a prospective AD screening program. The results of this study show that a screening CG test can be used as a tool to reduce diagnostic delays, improve long-term prognosis and reduce the healthcare costs of antibody deficiency | ||
700 | 1 | |a Jolles, Stephen |e verfasserin |4 aut | |
700 | 1 | |a Crescenzi, Ludovica |e verfasserin |4 aut | |
700 | 1 | |a Varricchi, Gilda |e verfasserin |4 aut | |
700 | 1 | |a Marone, Giancarlo |e verfasserin |4 aut | |
700 | 1 | |a Savoia, Marcella |e verfasserin |4 aut | |
700 | 1 | |a Genovese, Arturo |e verfasserin |4 aut | |
700 | 1 | |a Spadaro, Giuseppe |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Current pharmaceutical biotechnology |d Hilversum : Bentham Science Publ., 2000 |g 19(2018), 9, Seite 728- |h Online-Ressource |w (DE-627)KFL00000636X |w (DE-600)2044611-1 |w (DE-576)273880926 |x 1873-4316 |7 nnns |
773 | 1 | 8 | |g volume:19 |g year:2018 |g number:9 |g pages:728- |
856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=1389-2010&volume=19&issue=9&spage=728 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
912 | |a ZDB-1-BEJ | ||
912 | |a GBV_KFL | ||
912 | |a FID-PHARM | ||
912 | |a SSG-OLC-PHA | ||
935 | |i IMPORT_0628_prod_DARH_01 | ||
951 | |a AR | ||
952 | |d 19 |j 2018 |e 9 |h 728- |